ADGRD2 (adhesion G protein-coupled receptor D2), also known as GPR144, is a member of the adhesion GPCR superfamily 1. As an adhesion GPCR, ADGRD2 functions as a G protein-coupled receptor with signaling capability at the plasma membrane 1. While the provided abstracts do not detail ADGRD2's specific molecular mechanisms or primary physiological functions, the gene has emerging relevance in cancer biology and post-infectious disease pathophysiology. In uterine corpus endometrial carcinoma (UCEC), high ADGRD2 expression correlates with reduced relapse-free survival, suggesting prognostic significance in this malignancy 2. Additionally, ADGRD2 was identified in a genome-wide association study examining genetic modifiers of Post-COVID Syndrome, though the mechanistic connection remains unclear and the association did not reach stringent genome-wide significance 3. The adhesion GPCR family, including ADGRD2, represents an increasingly recognized class of pharmacologically important receptors with potential therapeutic applications 1. However, specific information regarding ADGRD2's ligands, signal transduction pathways, tissue-specific expression patterns, and detailed physiological roles requires further investigation beyond the provided literature.